Core Insights - The report emphasizes the emergence of "emotional consumption" as a significant trend in the retail industry, particularly benefiting brands that resonate with consumers' emotional needs [2][3][28] - The retail sector is experiencing a slow recovery, with varying performance across different segments, highlighting the resilience of brands linked to emotional value [3][10][39] Industry Review - In Q1 2025, social consumption showed a slow recovery, with retail businesses facing overall pressure. However, segments related to "emotional value" consumption, particularly leading brands, performed significantly better than the industry average [3][10][39] - The jewelry sector is under pressure due to high gold prices, while cross-border e-commerce remains stable but with profit pressures. The medical beauty and cosmetics sectors are facing intense competition, and offline retail is still exploring transformative models [3][6][39] Segment Analysis Jewelry - The jewelry industry is experiencing a shift in brand competition, with traditional brands facing challenges from differentiated product brands that are rapidly emerging and achieving high growth [6][39] - In Q1 2025, the jewelry sector's revenue was 431.6 billion yuan, down 25.9% year-on-year, with net profit also declining [39][64] Cosmetics - The cosmetics sector is benefiting from the rise of emotional consumption, with a focus on high-demand segments such as high-end beauty and differentiated personal care brands [5][39][64] - Brands like Mao Ge Ping and Proya are highlighted for their strong performance in this evolving market [5][39] Medical Beauty - The medical beauty sector is expected to recover as domestic demand increases, with a focus on differentiated product lines [5][39] - Companies like Ai Meike and Kedi-B are recommended for their unique offerings [5][39] Offline Retail - Offline retail is leveraging emotional consumption to regain market share, with companies like Yonghui Supermarket and Aiyingshi being recommended for their proactive transformation efforts [5][39] - The report notes that the shift towards a direct-to-consumer (DTC) model is crucial for offline retailers to enhance customer experience and emotional satisfaction [69] Investment Recommendations - For the jewelry sector, brands with differentiated product capabilities and deep consumer insights are recommended, including Lao Pu Gold and Chao Hong Ji [5][66] - In the cosmetics space, the report suggests focusing on high-demand segments and brands that can continuously innovate [5][66] - The medical beauty sector is advised to consider companies with unique product lines, such as Ai Meike and Kedi-B [5][66] - The report highlights the importance of emotional value in driving consumer preferences, suggesting that brands that can effectively tap into this trend will outperform their peers [5][66]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The retail sector is experiencing continuous operational pressure, with a focus on high-prosperity quality companies [4][24] - The overall revenue for the retail industry in 2024 and Q1 2025 decreased by 1.8% and 13.3% year-on-year, respectively, while the net profit attributable to the parent company decreased by 20.6% and 21.3% [4][24] - The report highlights the performance of various segments, including jewelry, beauty care, and cross-border e-commerce, with specific recommendations for investment opportunities [7][43] Summary by Relevant Sections Retail Market Overview - The retail industry index fell by 1.72% in the week of April 28 to April 30, 2025, underperforming the Shanghai Composite Index [6][15] - The beauty products segment showed the highest increase, with a weekly rise of 7.49% and a year-to-date increase of 12.66% [15][19] Industry Dynamics - The retail sector's financial reports indicate ongoing operational challenges, with a focus on high-prosperity segments [4][24] - The jewelry segment's revenue decreased by 4.9% in 2024 and 25.9% in Q1 2025, while the beauty care segment saw a revenue increase of 5.3% in 2024 but a slight decline of 1.7% in Q1 2025 [4][33][28] Investment Recommendations - Investment focus areas include traditional retail, jewelry, cosmetics, and medical aesthetics, with specific companies recommended for their growth potential [7][43] - Key recommended companies include Yonghui Supermarket, Aiyingshi, and various beauty brands such as Maogeping and Pulaia [7][46][44] Segment Performance - Cross-border e-commerce showed strong growth with a revenue increase of 31.9% in 2024 and 28.8% in Q1 2025, indicating a robust operational environment [4][38] - The beauty care segment is expected to maintain growth through differentiated products and strong brand positioning [28][44]

Investment Rating - The industry investment rating is optimistic (maintained) [1] Core Insights - Retail enterprises are under continuous operational pressure, with a focus on high-prosperity quality companies [4][24] - The overall revenue of the retail industry decreased by 1.8% in 2024 and 13.3% in Q1 2025, while the net profit attributable to the parent company decreased by 20.6% and 21.3% respectively [4][24] - The jewelry sector faced revenue declines of 4.9% in 2024 and 25.9% in Q1 2025, with net profit declines of 17.7% and 18.8% respectively [4][33] - The beauty care sector showed a revenue increase of 5.3% in 2024 but a slight decline of 1.7% in Q1 2025, with net profit declines of 17.5% and 21.7% respectively [4][28] - The cross-border e-commerce sector experienced significant growth, with revenue increases of 31.9% in 2024 and 28.8% in Q1 2025, while net profit showed a decline of 4.6% and an increase of 4.9% respectively [4][38] Summary by Sections Retail Market Overview - The retail industry index decreased by 1.72% in the week of April 28 to April 30, 2025, underperforming the Shanghai Composite Index [6][15] - The beauty products sector had the highest growth, with a weekly increase of 7.49% and a year-to-date increase of 12.66% [15][19] Industry Dynamics - The financial reports for 2024 and Q1 2025 indicate that retail enterprises are facing operational challenges, with a focus on high-prosperity sectors [4][24] - The jewelry sector is under pressure due to rising gold prices affecting consumer demand and operational challenges for weaker franchisees [4][33] - The beauty care sector remains relatively stable, with strong performance from differentiated beauty brands [4][28] Investment Recommendations - Focus on traditional retail companies that adapt to consumer trends, such as Yonghui Supermarket and Aiyingshi [7][43] - Highlight jewelry brands with differentiated product offerings, recommending brands like Laopu Gold and Chaohongji [7][43] - Emphasize domestic beauty brands that are expanding into high-prosperity segments, recommending brands like Maogeping and Shangmei [7][44] - Target upstream medical beauty product manufacturers with strong profitability, recommending companies like Aimeike and Kedi [7][44]

证券代码：603983 证券简称：丸美生物 公告编号：2025-014 广东丸美生物技术股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2024年年度股东大会 (二)股东大会召集人：董事会 至2025 年 5 月 22 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 (六)融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运作》等有 关规定执行。 (七)涉及公开征集股东投票权 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (四)现场会议召开 ...

2 0 2 4年在国货美妆发展史上是值得记录一年： 一方面，国内诞生首个突破百亿美妆企业，珀莱雅以1 0 7 . 7 8亿元营收首次跻身"百亿俱乐部"， 成 为 行 业 里 程 碑 事 件 ； 同 时 ， 十 强 门 槛 抬 高 至 近 3 0 亿 元 ， 前 十 总 营 收 规 模 扩 大 至 5 4 3 . 7 7 亿 元。 另一方面，前十座次发生较大变化，毛戈平首次闯入榜单，上海家化、华熙生物等企业持续步 入变革期深水区，迎来业绩"震荡"。 在"突飞猛进"与震荡调整并存的阶段，头部国货企业的发展预示着行业怎样的未来？ 综 合 2 0 2 1 年 至 2 0 2 4 年 国 货 美 妆 上 市 企 业 十 强 榜 单 情 况 来 看 ， 可 以 发 现 ， 名 次 发 生 了 较 大 变 化。每一年的前三名都不相同，并且持续有"突围者"闯入榜单，例如2 0 2 4年的毛戈平。 | | | | 2021年至2024年国货美妆上市企业十强榜单 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | -- ...

Investment Rating - The investment rating for the company is maintained as "Buy" [7] Core Views - The company has achieved high-quality revenue growth for nine consecutive quarters, with a revenue of 2.97 billion RMB in 2024, representing a year-on-year increase of 33.44%, and a net profit of 342 million RMB, up 31.69% year-on-year [1] - The main brand products, including the "Little Red Pen" eye cream and "Little Gold Needle" series, show strong momentum, with significant online sales growth [2] - The company is experiencing synergistic growth in both online and offline channels, with online revenue reaching 2.54 billion RMB in 2024, a year-on-year increase of 35.77% [3] Summary by Sections Revenue and Profitability - The company has reported a continuous double-digit revenue growth for nine quarters, with a net profit margin consistently above 9% [1] - In Q1 2025, the company achieved a revenue of 847 million RMB, a year-on-year increase of 28.01%, and a net profit of 135 million RMB, up 22.07% year-on-year [1] Product Performance - The "Little Red Pen" eye cream has been iterated to version 3.0, achieving an online GMV of 533 million RMB, a year-on-year increase of 146% [2] - The "Little Gold Needle" essence has also seen significant growth, with an online GMV of 350 million RMB, up 96% year-on-year [2] Cost and Expense Management - The sales expense ratio for 2024 was 55.0%, an increase of 1.19 percentage points year-on-year, reflecting increased investment in brand building and online competition [3] - The management expense ratio decreased to 3.7%, indicating improved cost efficiency [3] Profit Forecast and Valuation - The profit forecast for 2025-2027 has been adjusted, with expected net profits of 448 million RMB, 585 million RMB, and 758 million RMB respectively [4] - The target price has been raised to 50.40 RMB, based on a projected PE of 45 times for 2025 [4]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported strong performance in its major products, with online sales maintaining high growth [7] - The company has shown significant improvement in profitability and cost control, with gross margin increasing [7] - The dual-channel revenue growth is robust, with all four major product categories experiencing growth [7] - The company's brand strategy focusing on major products has enhanced user loyalty and brand performance [7] - The earnings forecast for 2025-2026 has been slightly adjusted downwards, but the long-term growth outlook remains positive [7] Financial Performance Summary - For 2024, total revenue is projected at 2,970 million, a year-on-year increase of 33.4% [7] - The net profit attributable to shareholders for 2024 is expected to be 341.63 million, up 31.7% year-on-year [7] - The gross margin for 2024 is forecasted to be 73.7%, an increase of 3.0 percentage points year-on-year [7] - Online revenue for 2024 is expected to reach 2,540 million, a growth of 35.8% [7] - The skincare category is projected to generate 1,125 million in revenue, a 21.6% increase [7] - The company's net profit margin for 2024 is estimated at 11.5%, a slight decrease of 0.2 percentage points year-on-year [7] Brand Performance Summary - The Marubi brand is expected to generate 2,055 million in revenue for 2024, a 31.69% increase [7] - The PL brand is projected to achieve 905 million in revenue for 2024, a growth of 40.72% [7] - The major product "Peptide Small Red Pen Eye Cream" has seen a significant increase in online sales, reaching 533 million, up 146% [7]

Investment Rating - The report maintains a "Strong Buy" rating for the company [1][8]. Core Views - The company shows strong performance with a projected revenue growth of 33% and a net profit growth of 32% for 2024, continuing into Q1 2025 with revenue growth of 28% and net profit growth of 22% [1][2]. - The dual-brand strategy, featuring the main brand Marubi and the PL brand Lianhuo, is driving growth, with significant contributions from key products like the Marubi Eye Cream and the Golden Needle series [1][3]. - The company is expected to achieve net profits of 445 million, 549 million, and 643 million yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 30%, 23%, and 17% [1][8]. Financial Performance - In 2024, the company achieved a total revenue of 2.97 billion yuan, a year-on-year increase of 33.44%, and a net profit of 342 million yuan, up 31.69% [2][9]. - The main brand Marubi generated revenue of 2.06 billion yuan in 2024, growing by 31.69%, while the PL brand Lianhuo achieved 905 million yuan, a growth of 40.72% [3][9]. - The company's gross margin improved to 73.70% in 2024, up by 3.01 percentage points, attributed to product structure optimization and cost control [7][12]. Product and Channel Analysis - The company’s product categories showed strong performance, with eye care products generating 689 million yuan in revenue, a 60.78% increase, and skincare products reaching 1.13 billion yuan, up 21.60% [3][9]. - Online sales channels contributed significantly, with revenue of 2.54 billion yuan in 2024, reflecting a growth of 35.77%, while offline channels saw a 20.79% increase to 427 million yuan [3][9]. Future Outlook - The company is expected to continue its growth trajectory with a stable cash flow and a focus on product innovation, which is anticipated to contribute to incremental growth [8][9]. - The projected earnings per share (EPS) for 2025 is 1.11 yuan, with a price-to-earnings (PE) ratio of 39.3 [9][12].

Group 1: Fixed Income Market - The recent volatility in the US Treasury market is largely attributed to the upcoming June maturity, which may be overestimated in terms of its impact on financial markets [2] - In the short term, the supply pressure from maturing US Treasuries is expected to be limited, with a more significant focus on the debt ceiling adjustments anticipated in Q3 [2] - Long-term demand for US Treasuries may face a downward trend, with potential alternatives including European and Japanese bonds, as well as gold [2] Group 2: Technology Sector - The report discusses India's potential as the next manufacturing hub for Apple, highlighting the competitive tariff advantages for Indian exports compared to China [4] - Apple theoretically has the capacity to produce the required number of iPhones in India, but initial production will still rely on Chinese exports due to current limitations [4] - The localization of components in India is still in its early stages, with significant reliance on supply chains from other Asian countries for critical parts [4] Group 3: Energy and New Energy - The lithium battery production forecast for May shows a slight decline in overall production, primarily due to the cancellation of mandatory storage policies and the impact of US tariffs on exports [5] - Despite short-term fluctuations, the long-term outlook for the lithium battery industry remains positive, driven by new vehicle models and technologies [5] - Recent power outages in Spain, Portugal, and southern France have underscored the need for investment in grid upgrades and DC grid technology, presenting opportunities for Chinese power equipment companies [6] Group 4: Media and Publishing - Phoenix Media reported a Q1 2025 revenue of 3.226 billion yuan, reflecting a year-over-year decline, but a significant increase in net profit due to continued tax incentives [7] - The company maintains a stable core business and is rated as a "buy" based on its solid performance and favorable tax policies [7] Group 5: Financial Sector - The report indicates that the China Construction Bank's Q1 2025 net profit and revenue showed slight year-over-year changes, with a focus on asset quality and credit expansion [9] - The bank's diversified income sources and stable operations support a "buy" rating [9] Group 6: Consumer Goods - The report highlights the strong performance of China National Offshore Oil Corporation, with Q1 revenues showing a significant year-over-year increase, driven by stable oil and gas production [20] - The company is expected to maintain a "buy" rating due to its robust operational performance and project advancements [20] Group 7: Real Estate - The report notes that China Petroleum's Q1 2025 revenue and net profit exceeded expectations, attributed to increased natural gas production and sales [34] - The company is rated as "increase" based on its strong performance and potential for further growth in the natural gas sector [34]

Investment Rating - The investment rating for Marubi Biotechnology (丸美生物) is not explicitly stated in the provided documents, but the overall sentiment appears positive based on the performance metrics and growth projections. Core Insights - Marubi Biotechnology reported a revenue of 2.97 billion yuan in 2024, representing a year-over-year increase of 33.4%, with a net profit attributable to shareholders of 342 million yuan, up 31.7% year-over-year [1] - The company is experiencing continuous growth driven by both product innovation and technological advancements, positioning itself as a leader in the collagen industry [5] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 2.97 billion yuan and a net profit of 342 million yuan, with a significant increase in net profit margin [1] - For Q1 2025, revenue reached 847 million yuan, reflecting a year-over-year growth of 28% [1] - The gross profit margin improved to 74.6% in 2024, with a further increase to 76% in Q1 2025 [4] Product and Brand Development - The product structure is continuously optimized, with skincare, eye care, cleansing, and beauty products generating revenues of 1.125 billion, 689 million, 241 million, and 913 million yuan respectively in 2024 [2] - The eye care segment saw significant growth, particularly with the "胜肽小红笔眼霜" product, which achieved an online GMV of 533 million yuan, up 146% year-over-year [2] Sales Channels - Online sales accounted for 25.41 billion yuan in 2024, growing by 35.8% year-over-year, while offline sales reached 4.27 billion yuan, up 20.8% [3] - The online sales proportion increased to 86%, indicating a strong digital presence and effective multi-platform strategies [3] Cost Management and Efficiency - The company maintained stable expense ratios across sales, management, and R&D, with a sales expense ratio of 55% in 2024 [4] - Inventory turnover days improved to approximately 90.2 days in 2024, indicating enhanced operational efficiency [4] Future Projections - The forecast for net profit attributable to shareholders is projected to be 450 million yuan in 2025, 582 million yuan in 2026, and 692 million yuan in 2027, reflecting a consistent growth trajectory [8] - The expected P/E ratios for 2025, 2026, and 2027 are 38.9X, 30.1X, and 25.3X respectively, suggesting a favorable valuation outlook [6]